A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Clinical trial NCT01647711 · COMPLETED

Trial details

NCT number: NCT01647711
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2012-07-01
Primary completion: 2015-09-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.